MOTS-c

Steady

MOTS-c appears in 267 indexed publications going back to 2015, including 55 in the past twelve months. 4 registered trials appear on ClinicalTrials.gov.

267
Indexed publications
55
Past 12 months, against 46 the year before
4
Registered clinical trials
4,712
Monthly readers on Wikipedia, down 6%
Research Activity

Publication history

How much work has been indexed each year, from Europe PMC. Momentum is measured over a trailing twelve months rather than calendar years, so a partial current year never reads as a decline.

20152026

Publications per year. The final bar is the current year, still in progress.

Indexed publications per year
20154
20163
20173
201813
201922
202014
202131
202222
202335
202432
202546
202641
Public Attention

Who is looking it up

Monthly readers of the MOTS-c article on English Wikipedia. An independent measure of curiosity, which often moves quite differently from the evidence.

2025-082026-07
Clinical Trials

The registered pipeline

Early Phase 1
0
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0

Phase distribution across the most recently updated registered trials.

References

Most recent work

The newest indexed records mentioning MOTS-c, listed by publication date. Titles are shown as published and link to their source. Inclusion here is a record of what exists, not a judgement of what it shows.

  1. 2026-05-12·Life sciences

    MOTS-c attenuates hyperoxia-induced neonatal cardiac injury by inhibiting oxeiptosis via maintaining the KEAP1-PGAM5 interaction

    Li SH, Chen SQ, Lu T et al.

  2. 2026-05-09·Redox biology

    LAT1-mediated delivery of engineered R13A-MOTS-c attenuates radiation-induced lung injury via Nrf2 activation and mitochondrial protection

    Zhang YL, Huang G, Li SP et al.

  3. 2026-03-31·Free radical biology & medicine

    Mitochondrial-derived peptide MOTS-c targets SLC7A11 to preserve spermatogenesis by suppressing ferroptosis

    Liu S, Ru K, Shen YJ et al.

  4. 2026-06-25·Experimental physiology

    Circulating mitochondrial-derived microproteins at rest and in response to an acute bout of endurance exercise in individuals with cerebral palsy

    Horwath O, Corell L, Wan J et al.

  5. 2026-06-22·Inflammation and regeneration

    Mitochondrial-derived peptide MOTS-c activates metabolic signaling but blunts reparative function in human mesenchymal stromal cells

    Xing L, Lu B, Zhu X et al.

  6. 2026-06-19·Experimental physiology

    Mitochondrial peptide MOTS-c suppresses systemic and cardiac inflammasome activation in a diabetic rat model

    Mills AR, de Souza A, Pham T et al.

  7. 2026-06-04·Journal of translational medicine

    MOTS-c: How a secreted mitochondrial microprotein may become a potential treatment for inflammatory lung diseases

    Amado CA, Agüero J, García-Unzueta M et al.

  8. 2026-06-02·Molecular biology reports

    MOTS-c preserves mitochondrial subpopulation bioenergetics and genome integrity to attenuate cardiac ischemia reperfusion injury

    Santhanam SS, Jayaraman S, Rajesh SS et al.

In the Catalogue

MOTS-c available from Polaris Research

Supplied as research materials for laboratory use. Free express delivery Australia wide.

Sources

Publication data from Europe PMC. Clinical trial data from ClinicalTrials.gov, U.S. National Library of Medicine. Public attention from Wikimedia pageview data. Evidence grades from reptides.co. We report counts and dates from these sources and link every record to its origin, we do not summarise findings. Last synced 2026-08-02.